FDA advisory committee voted yes on BPC-157, TB-500, KPV, and MOTS-c — here’s what that actually changes
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee did something most industry observers were not expecting: it voted yes on all four Day 1 peptides — BPC-157, TB-500, KPV, and MOTS-c — recommending that each be added to the 503A Bulk Drug Substances List, overriding the agency’s own scientists. BPC-157 cleared by a margin of 8–6, making it the closest vote and the most-watched call. The results land at a charged moment: the FDA’s own staff had publicly recommended against all seven compounds just weeks before the hearing, citing inadequate human clinical data. That the committee voted the other way matters — but what it actually changes for anyone accessing these compounds right now is more limited than headlines suggest.
The vote, compound by compound
Day 1 of the hearing covered BPC-157, KPV, TB-500, and MOTS-c. BPC-157 went first and drew the most public comment testimony — more than 1,200 submissions from patients, researchers, and clinicians were submitted to the docket before the July 9 deadline. The committee voted 8–6 in favor, with one abstention. KPV passed 8–6 with one abstention as well; TB-500 also received a favorable vote; MOTS-c cleared 7–5 with two abstentions. On Day 2 (July 24), the committee reviewed Semax, Epithalon, and DSIP (Emideltide). Semax passed 8–5 with one abstention. Epithalon passed 7–5 with one abstention. Emideltide (DSIP) was the single compound voted down — committee members cited insufficient evidence of clinical need and the availability of already-approved treatments for its proposed indications, which included opioid withdrawal, chronic insomnia, and narcolepsy. The final tally across both days: six recommended, one (Emideltide/DSIP) not recommended. Sources: NYT (July 24, 2026); RAPS (July 24, 2026); peptidedossier.com PCAC summary.
What “FDA staff recommended against” actually means
The pre-hearing briefing documents, published July 13, had FDA scientists recommending against adding all seven peptides to the 503A list — citing inadequate characterization for human use, insufficient clinical need relative to available alternatives, and manufacturing impurity concerns specific to synthetic peptide production. Staff positions are data-driven analyses from career scientists, not political recommendations; they carry significant weight with the committee. The fact that PCAC overrode the staff position on six of seven compounds is the clearest sign of how much the political and public health environment shifted between 2023 — when these compounds were categorized as “do not compound” — and today. The PCAC is composed of physicians, pharmacists, and research scientists who are not FDA employees and are not bound by staff conclusions; they weigh the same data but also take public testimony and patient-reported outcomes into account.
What a yes vote does and doesn’t do
This is the part most coverage gets wrong. A favorable PCAC recommendation is not approval, it is not reclassification, and it does not open a new buying channel. What it does is authorize the FDA to move to formal rulemaking — publishing a proposed rule in the Federal Register, opening a new comment period, and eventually issuing a final rule. This process typically takes 12 to 24 months from the date of the PCAC vote. Until that rulemaking concludes, compounding pharmacies cannot legally prepare BPC-157, TB-500, KPV, or MOTS-c under 503A even under the favorable PCAC recommendation. And even after final rulemaking, 503A access requires a prescriber relationship and individual prescription — it does not create a direct-to-consumer retail or “research use only” pathway. The grey-market vial model most vendors currently operate under is not affected one way or the other by this vote.
How we got here: the political backstory
The momentum behind these favorable votes traces to February 2026, when HHS Secretary Robert F. Kennedy Jr. announced that roughly 14 of the 19 peptides that had been placed on the “do not compound” list in 2023 would be moved off — described publicly as a Make America Healthy Again (MAHA) policy priority. The FDA followed with formal Category 2 removals effective April 22–23, 2026. What the February announcement signaled, and the April removal confirmed, was a shift in the FDA’s enforcement posture. What July 23 confirmed is that PCAC members — most of whom are physicians, pharmacists, and research scientists, not political appointees — reached the same conclusion about clinical need and benefit-risk despite their own staff’s reservations. The eight yes votes on BPC-157 included committee members who represent or advise telehealth companies, drawing some criticism that conflicts of interest skewed the margin.
The enforcement backdrop that hasn’t changed
None of this softens the parallel enforcement environment. The sentencing hearing for Matthew Kawa (Paradigm Peptides / Amino Asylum) and his co-defendant Jennifer Stechkober is set for July 30, 2026 — one week after the PCAC vote. Both pleaded guilty earlier this year to distributing unapproved drugs at scale. In April 2026, a Utah physician was indicted for prescribing misbranded peptides sourced from Chinese manufacturers to more than 200 of his own patients. Customs and Border Protection continues to flag and seize peptide shipments arriving from overseas suppliers. A PCAC recommendation in favor of 503A listing for BPC-157 does not change any of that — the legal exposure for grey-market vendors and offshore-sourced product is exactly what it was the day before the vote. The PCAC’s work and the criminal enforcement track operate on entirely separate legal rails.
What researchers should watch next
The next procedural milestone is the FDA’s formal response to the PCAC recommendations — typically a Federal Register notice of proposed rulemaking published within a few months of the hearing. Watch specifically for whether the FDA accepts all six favorable recommendations, partially accepts them, or declines to follow the committee’s advice. On the GLP-1 side, the agency is simultaneously processing more than 40,000 public comments received before the June 29 deadline on its proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B list; a final rule on that docket is expected within 6–12 months. The two tracks — peptide access opening, GLP-1 compounding closing — represent the most consequential dual shift in U.S. compounding policy in a generation. Peptide Hub will continue tracking both and will update database entries as formal rulemaking progresses.
Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.
Sources
- ABC News — FDA advisory committee votes to add BPC-157 to compounding list: abcnews.go.com
- NPR — Advisers to the FDA vote to ease regulation of popular peptides: npr.org
- MarketWatch — Most FDA advisers say peptides like BPC-157 and TB-500 should be available: marketwatch.com
- TIME — An FDA committee just voted in favor of peptides despite agency opposition: time.com
- RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list: raps.org
- FDA.gov — July 23-24, 2026 PCAC meeting calendar: fda.gov